Extended Data Fig. 6: Novel Mrc1^CreERT2/+ mouse.

(A) Experimental procedure for tamoxifen administration (TAM) and analysis of adult Mrc1^+/+R26^tdTM/+ or Mrc1^CreERT2/+R26^tdTM/+ mice. (B-D) Immunofluorescence images reveal tdTM⁺ (red) in CD206⁺ BAM (green) in perivascular macrophages (pvMΦ) (B), pial MΦ (c), and dural MΦ (D). CD31⁺ blood vessels shown in cyan. Scale bars: 20 μm. (E) TdTM expression was no observed in microglia (IBA1⁺, green) of adult Mrc1^CreERT2/+R26^tdTM/+ mice. Scale bars: 20 μm. (F) Quantification of recombination efficacy in pvMΦ, pial MΦ, and dural MΦ, as well as microglia in Mrc1^+/+R26^tdTM/+ and Mrc1^CreERT2/+R26^tdTM/+ mice. Data shown as mean ± SEM; Mrc1^+/+R26^tdTM/+ n = 5 mice per compartment except n = 3 mice for dura; and Mrc1^CreERT2/+R26^tdTM/+ n = 6 mice for pvMΦ and pial, and n = 5 mice for dural and microglia. (G) Experimental procedure for tamoxifen administration and analysis of Mrc1^CreERT2/+ x IL17RA^flox/flox mice. (H) Representative image of cerebral blood vessel stained for CD31 (yellow, IHC), Mrc1 (cyan, RNAscope) and IL17RA (magenta, RNAscope). Blood vessel shows one IL17RA- BAM and one IL17RA + BAM. This identification strategy was used for quantification of IL17RA deletion in Mrc1^CreERT2/+ x IL17RA^flox/flox mice. Scale bars: 10 μm.

Source data